SH2D3A (SH2 domain containing 3A) is a signaling protein that plays multiple roles in cancer progression and cellular regulation. The protein exhibits oncogenic properties in several cancer types, with elevated expression associated with poor patient prognosis in lung cancer 1, uveal melanoma 2, and cholangiocarcinoma 3. SH2D3A expression is regulated by hypoxia through HIF-2α-mediated transcriptional activation, and the protein contributes to cancer stem cell maintenance and malignant behaviors including uncontrolled self-replication and proliferation 1. In cervical cancer, SH2D3A is regulated by the HPV E7/miR-143-3p pathway and functions through modulation of the JAK1/STAT3 signaling cascade 4. The protein's knockdown inhibits cell proliferation and invasion while inducing apoptosis, suggesting it as a potential therapeutic target 4. Additionally, SH2D3A has been implicated in longevity mechanisms, with rare variants identified in long-lived families 5. While UniProt annotations suggest a role in JNK cascade activation, the current literature primarily demonstrates SH2D3A's involvement in oncogenic processes across multiple cancer types, making it a promising biomarker and therapeutic target.